Pharmaceutical major Lupin Limited plans to increase its contract manufacturing business for its international clients and has appointed a new CEO. 

They have appointed Abdelaziz Toumi as the Chief Executive Officer of the company’s subsidiary, Lupin Manufacturing Solutions (LMS), which is a unit that is starting to build its Contract Development and Manufacturing Operations (CDMO) business for global clients. 

Abdelaziz Toumi is regarded as a highly experienced leader in the industry and also has more than two decades of experience in biotech, pharma, and CDMO sectors across North America, Europe, and Asia. 

Toumi has held leadership roles at Merck, Bayer, KBI Biopharma, Catalent, and Lonza, and has also worked at Lupin in the past. 

Nilesh Gupta, Managing Director of Lupin, said, “brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.”

Earlier in September 2023, the company had signed a business transfer agreement with LMS to transfer two API manufacturing sites and select R&D operations to the company. 

Lupin is the third-largest pharma company in the US on the basis of prescriptions. The company operates 15 manufacturing sites and 7 research centres globally.